Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/120023
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRipoll Llagostera, Èlia-
dc.contributor.authorRamon, Laura de-
dc.contributor.authorBordignon Draibe, Juliana-
dc.contributor.authorMerino, Ana-
dc.contributor.authorBolaños, Núria-
dc.contributor.authorGomà, Montse-
dc.contributor.authorCruzado, Josep Ma.-
dc.contributor.authorGrinyó Boira, Josep M.-
dc.contributor.authorTorras Ambròs, Joan-
dc.date.accessioned2018-02-20T09:46:03Z-
dc.date.available2018-02-20T09:46:03Z-
dc.date.issued2016-06-08-
dc.identifier.issn1478-6362-
dc.identifier.urihttp://hdl.handle.net/2445/120023-
dc.descriptionEs va publicar un erratum de l'article a: Arthritis Research & Therapy, 2016, vol. 18 , num. 1, p. 152-
dc.description.abstractBackground: Lupus nephritis (LN) is a complex chronic autoimmune disease of unknown etiology characterized by loss of tolerance against several self-antigens. Cytokines are known to be central players in LN pathogenesis. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is one important pathway that mediates signal transduction of several cytokines. In this study, we examined the pathogenic role of this pathway and how CP-690,550 treatment influences LN outcome. Methods: Six-month-old NZB/NZWF1 mice were divided into two different treatment groups: (1) control animals given vehicle treatment, cyclophosphamide, and mycophenolate mofetil treatment as positive controls of the therapy and (2) mice treated with CP-690,550, a JAK3 inhibitor. Mice were treated for 12 weeks. We evaluated renal function, anti-double-stranded DNA (anti-dsDNA) antibody, renal histology changes, kidney complement and immunoglobulin G (IgG) deposits, T-cell and macrophage infiltration, kidney inflammatory gene expression, and circulating cytokine changes. Results: CP-690,550 treatment significantly reduced proteinuria and improved renal function and histological lesions of the kidney. Compared with vehicle-treated animals, those undergoing CP-690,550 treatment showed significantly diminished anti-dsDNA antibody and complement component C3 and IgG deposition in glomeruli. We also observed a significant reduction of T-cell and macrophage infiltration. Kidney gene expression revealed a reduction in inflammatory cytokines and complement and related macrophage-attracting genes. Circulating inflammatory cytokines were also reduced with treatment. Conclusions: On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the course of experimental LN. Thus, CP-690,550 could become a new therapeutic tool in LN and other autoimmune diseases.-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s13075-016-1034-x-
dc.relation.ispartofArthritis Research & Therapy, 2016, vol. 18 , num. 1, p. 134-
dc.relation.urihttps://doi.org/10.1186/s13075-016-1034-x-
dc.rightscc-by (c) Ripoll Llagostera, Èlia et al., 2016-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationLupus-
dc.subject.classificationMalalties autoimmunitàries-
dc.subject.classificationCitoquines-
dc.subject.classificationRatolins (Animals de laboratori)-
dc.subject.otherLupus-
dc.subject.otherAutoimmune diseases-
dc.subject.otherCytokines-
dc.subject.otherMice (Laboratory animals)-
dc.titleJAK3-STAT pathway blocking benefits in experimental lupus nephritis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec666380-
dc.date.updated2018-02-20T09:46:03Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid27278657-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
666380.pdf2.2 MBAdobe PDFView/Open
666380 Erratum.pdf333.91 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons